Clinical Trial Search

Primary: Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing…

Primary: Number of Patients With Adverse Events — 5; 2; 5; 2 participants

Primary: Change From Baseline in Trough FEV1 at Week 12 — -0.013; -0.031; 0.062; 0.099 Liters — p=0.437

Primary: ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12 — 7.1; 26.8; 41.5; 46.3 percentage of subjects — p==0.031

Primary: Number of Patients With Serious Bleeding Events — 0; 1 Participants

Primary: Cohort 1 - Number of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate) — 1 Participants

Primary: Feasibility of Enrolling Eligible Stroke Patients Admitted to Inpatient Rehabilitation for an Acute Ischemic or Hemorrhagic Stroke Into a Pilot, Randomized Clinical…

Primary: British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA) — 8; 8 Participants — p=>0.999

Primary: Change in Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) Average Score From Baseline — 0.28; 0.28; 0.28; 0.33 score on a scale

Primary: 2-year Metastasis-Free Survival Rate — 42.3; 41.8 percent probability — p=0.97

Primary: Percentage of Patients With Normalised Testosterone After 24 Weeks of Study Treatment — 59; 62; 63; 7 Participants

Primary: Measurement of Sleepiness Using the Epworth Sleepiness Scale (ESS) at Baseline and Post Dose. — -4.34; -4.64; -3.46; -4.73 units on a scale — p=0.668

Primary: Number of Participants With Radiographic Response — 4 Participants

Primary: Percent Change in Fasting Triglyceride Levels — 55.76 percentage of change from baseline

Primary: Number of Participants That Were 2-level Composite (CR-PCSS and PR-PCSS) Responders During the Observation Phase — 19; 0; 16; 0 Participants